Source: ERS Course 2021 - COVID-19: State of the art



Rating:

Share or cite this content

Citations should be made in the following way:
F. Blasi (Milan, Italy). Management of COVID-19: Drugs anti-inflammatories. ERS Course 2021 - COVID-19: State of the art

Member's Comments

No comment yet.

Related content which might interest you: Management of COVID-19: Drugs anti-virals Source: ERS Course 2021 - COVID-19: State of the art Year: 2021 Drugs anti-inflammatories Source: Virtual Congress 2020 – Management Year: 2020 Drugs anti-virals Source: Virtual Congress 2020 – Management Year: 2020 Workshop: Antibiotics Source: Research Seminar 2006 - Preventing respiratory sequelae in children diagnosed with cystic fibrosis by newborn screening Year: 2006 Dupilumab (DPL) Efficacy in Patients With Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with/without Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): SINUS-24, SINUS-52 Trials Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019 Prescribing Trends of Oral Corticosteroids Among Young Adults with Active Asthma Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014 Targeting neuropetides: from antiemetics to bronchodilators? Source: Annual Congress 2012 - ERS Romain Pauwels Research Award Ceremony (supported by GlaxoSmithKline) followed by the Hot Topic "The nerves are back!" Year: 2012 Severe Asthma, Current Options and Limitations of Pharmacotherapy Source: Research Seminar 2007 - Severe Asthma Year: 2007 Anti-tuberculosis drugs Source: International Congress 2017 – State of the art session: "Respiratory infections" Year: 2017 Integrated safety across six clinical trials of alpha-1 augmentation therapy Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Comparison of three modalities of corticosteroids administration in chronic rhinosinusitis Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 LATE-BREAKING ABSTRACT: Blood Eosinophil Count as a Biomarker of ICS Effectiveness in Reducing Exacerbation Rates in COPD Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 LATE-BREAKING ABSTRACT: Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in COPD? Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Introduction to The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study Source: Eur Respir J 2002; 20: Suppl. 38, 426s Year: 2002 Effect of Antifibrotic Therapies in Patients with Interstitial Pneumonia with Autoimmune Features Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Late Breaking Abstract - SUPRAnav: A Clinical Trial Evaluating the Efficacy and Safety of a New Invention Device Designed for Continuous Supraglottic Aspiration in Mechanically Ventilated Patients. Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection Year: 2019 Guideline Adherence and Identifying Cost Effective Medication Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014